﻿               SEQUENCE LISTING

<110> Julius-Maximilians-Universität Würzburg

<120> Affinity matured and humanized binding domains targeting ROR2

<130> 234869

<150> EP 20 163 019.1
<151> 2020-03-13

<160> 54

<170> BiSSAP 1.3.6

<210> 1
<211> 114
<212> PRT
<213> Artificial Sequence


<220> 
<223> XBR2-401 VH sequence

<400> 1
Gln Ser Val Lys Glu Ser Glu Gly Gly Leu Phe Lys Pro Thr Asp Thr 
1               5                   10                  15      
Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Gly 
            20                  25                  30          
Val Thr Trp Val Arg Gln Ala Pro Gly Ser Gly Leu Glu Trp Ile Gly 
        35                  40                  45              
Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys Ser 
    50                  55                  60                  
Arg Ser Thr Ile Thr Arg Asn Thr Asn Glu Asn Thr Val Thr Leu Lys 
65                  70                  75                  80  
Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 
                85                  90                  95      
Asp Trp Thr Ser Leu Asn Ile Trp Gly Pro Gly Thr Leu Val Thr Val 
            100                 105                 110         
Ser Ser 
        

<210> 2
<211> 110
<212> PRT
<213> Artificial Sequence


<220> 
<223> XBR2-401 VL sequence

<400> 2
Asp Pro Met Leu Thr Gln Thr Pro Ser Ser Thr Ser Thr Ala Val Gly 
1               5                   10                  15      
Asp Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Asp 
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile 
        35                  40                  45              
Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly 
    50                  55                  60                  
Ser Gly Tyr Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Arg 
65                  70                  75                  80  
Glu Asp Ala Ala Ile Tyr Tyr Cys Leu Gly Gly Tyr Ala Asp Ala Ser 
                85                  90                  95      
Tyr Arg Thr Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110 

<210> 3
<211> 115
<212> PRT
<213> Artificial Sequence


<220> 
<223> X3.12 VH sequence

<400> 3
Gln Ser Val Lys Glu Ser Glu Gly Gly Leu Phe Lys Pro Thr Asp Thr 
1               5                   10                  15      
Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Gly 
            20                  25                  30          
Val Thr Trp Val Arg Gln Ala Pro Gly Ser Gly Leu Glu Trp Ile Gly 
        35                  40                  45              
Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys Ser 
    50                  55                  60                  
Arg Ser Thr Ile Thr Arg Asn Thr Asn Glu Asn Thr Val Thr Leu Lys 
65                  70                  75                  80  
Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 
                85                  90                  95      
Asp Asp Arg Trp Ser Leu Asn Ile Trp Gly Pro Gly Thr Leu Val Thr 
            100                 105                 110         
Val Ser Ser 
        115 

<210> 4
<211> 110
<212> PRT
<213> Artificial Sequence


<220> 
<223> X3.12 VL sequence

<400> 4
Asp Pro Met Leu Thr Gln Thr Pro Ser Ser Thr Ser Thr Ala Val Gly 
1               5                   10                  15      
Asp Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Asp 
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile 
        35                  40                  45              
Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly 
    50                  55                  60                  
Ser Gly Tyr Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Arg 
65                  70                  75                  80  
Glu Asp Ala Ala Ile Tyr Tyr Cys Leu Gly Gly Tyr Ala Asp Ala Ser 
                85                  90                  95      
Tyr Arg Thr Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110 

<210> 5
<211> 116
<212> PRT
<213> Artificial Sequence


<220> 
<223> hX3.12.5 VH sequence

<400> 5
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Tyr 
            20                  25                  30          
Gly Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              
Ser Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  
Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      
Arg Asp Asp Arg Trp Ser Leu Asn Ile Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         
Thr Val Ser Ser 
        115     

<210> 6
<211> 110
<212> PRT
<213> Artificial Sequence


<220> 
<223> hX3.12.5 VL sequence

<400> 6
Asp Pro Met Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Asp 
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              
Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly 
    50                  55                  60                  
Ser Gly Tyr Gly Thr Glu Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Ala Asp Ala Ser 
                85                  90                  95      
Tyr Arg Thr Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110 

<210> 7
<211> 116
<212> PRT
<213> Artificial Sequence


<220> 
<223> hX3.12.6 VH sequence

<400> 7
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          
Gly Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              
Ser Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  
Ser Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu 
65                  70                  75                  80  
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      
Arg Asp Asp Arg Trp Ser Leu Asn Ile Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         
Thr Val Ser Ser 
        115     

<210> 8
<211> 15
<212> PRT
<213> Artificial Sequence


<220> 
<223> 4(GS)x3 linker

<400> 8
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  

<210> 9
<211> 232
<212> PRT
<213> Artificial Sequence


<220> 
<223> hinge, CH2 (aglycosylation mutation) and CH3 (N297A)

<400> 9
Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
            20                  25                  30          
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
        35                  40                  45              
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
    50                  55                  60                  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
65                  70                  75                  80  
Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
                85                  90                  95      
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
            100                 105                 110         
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
        115                 120                 125             
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr 
    130                 135                 140                 
Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser 
145                 150                 155                 160 
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
                165                 170                 175     
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
            180                 185                 190         
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
        195                 200                 205             
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
    210                 215                 220                 
Ser Leu Ser Leu Ser Pro Gly Ala 
225                 230         

<210> 10
<211> 120
<212> PRT
<213> Artificial Sequence


<220> 
<223> V9 scFV heavy chain variable domain (VH)

<400> 10
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          
Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              
Ala Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  
Lys Asp Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      
Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp 
            100                 105                 110         
Gly Gln Gly Thr Leu Val Thr Val 
        115                 120 

<210> 11
<211> 17
<212> PRT
<213> Artificial Sequence


<220> 
<223> (G4S)x3 linker

<400> 11
Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
1               5                   10                  15      
Ser 
    

<210> 12
<211> 107
<212> PRT
<213> Artificial Sequence


<220> 
<223> V9 scFV light chain variable domain (VL)

<400> 12
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 
            20                  25                  30          
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              
Tyr Tyr Thr Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp 
                85                  90                  95      
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         

<210> 13
<211> 232
<212> PRT
<213> Artificial Sequence


<220> 
<223> hinge, CH2 (aglycosylation mutation) and CH3 (N297A)

<400> 13
Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 
1               5                   10                  15      
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
            20                  25                  30          
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
        35                  40                  45              
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 
    50                  55                  60                  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
65                  70                  75                  80  
Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
                85                  90                  95      
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 
            100                 105                 110         
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
        115                 120                 125             
Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 
    130                 135                 140                 
Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser 
145                 150                 155                 160 
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
                165                 170                 175     
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val 
            180                 185                 190         
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 
        195                 200                 205             
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
    210                 215                 220                 
Ser Leu Ser Leu Ser Pro Gly Ala 
225                 230         

<210> 14
<211> 22
<212> PRT
<213> Artificial Sequence


<220> 
<223> GMCSF signal peptide

<400> 14
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 
1               5                   10                  15      
Ala Phe Leu Leu Ile Pro 
            20          

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> Partial amino acid sequence of human ROR1 from Figure 8

<400> 15
Phe Lys Ser Asp 
1               

<210> 16
<211> 12
<212> PRT
<213> Artificial Sequence


<220> 
<223> IgG4 hinge

<400> 16
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro 
1               5                   10          

<210> 17
<211> 28
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD28 transmembrane domain

<400> 17
Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser 
1               5                   10                  15      
Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 
            20                  25              

<210> 18
<211> 112
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD3z signaling domain

<400> 18
Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 
1               5                   10                  15      
Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 
            20                  25                  30          
Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 
        35                  40                  45              
Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 
    50                  55                  60                  
Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 
65                  70                  75                  80  
Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 
                85                  90                  95      
Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 
            100                 105                 110         



<210> 19
<211> 24
<212> PRT
<213> Artificial Sequence


<220> 
<223> T2A ribosomal skipping sequence

<400> 19
Leu Glu Gly Gly Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp 
1               5                   10                  15      
Val Glu Glu Asn Pro Gly Pro Arg 
            20                  

<210> 20
<211> 335
<212> PRT
<213> Artificial Sequence


<220> 
<223> EGFRt

<400> 20
Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys Asp Ser Leu 
1               5                   10                  15      
Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys Asn Cys Thr Ser Ile 
            20                  25                  30          
Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe Arg Gly Asp Ser Phe 
        35                  40                  45              
Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu Asp Ile Leu Lys Thr 
    50                  55                  60                  
Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln Ala Trp Pro Glu Asn 
65                  70                  75                  80  
Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg Gly Arg 
                85                  90                  95      
Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val Ser Leu Asn Ile 
            100                 105                 110         
Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly Asp Val 
        115                 120                 125             
Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr Ile Asn Trp 
    130                 135                 140                 
Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr Lys Ile Ile Ser Asn 
145                 150                 155                 160 
Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln Val Cys His Ala Leu 
                165                 170                 175     
Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro Arg Asp Cys Val Ser 
            180                 185                 190         
Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val Asp Lys Cys Asn Leu 
        195                 200                 205             
Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys Ile Gln 
    210                 215                 220                 
Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys Thr Gly 
225                 230                 235                 240 
Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp Gly Pro 
                245                 250                 255     
His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly Glu Asn Asn Thr 
            260                 265                 270         
Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val Cys His Leu Cys His 
        275                 280                 285             
Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly Leu Glu Gly Cys Pro 
    290                 295                 300                 
Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr Gly Met Val Gly Ala 
305                 310                 315                 320 
Leu Leu Leu Leu Leu Val Val Ala Leu Gly Ile Gly Leu Phe Met 
                325                 330                 335 

<210> 21
<211> 19
<212> PRT
<213> Artificial Sequence


<220> 
<223> Human Ig heavy chain signal peptide

<400> 21
Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly 
1               5                   10                  15      
Ala His Ser 
            

<210> 22
<211> 79
<212> PRT
<213> Artificial Sequence


<220> 
<223> Partial amino acid sequence of human ROR2

<400> 22
Cys Tyr Asn Gly Ser Gly Met Asp Tyr Arg Gly Thr Ala Ser Thr Thr 
1               5                   10                  15      
Lys Ser Gly His Gln Cys Gln Pro Trp Ala Leu Gln His Pro His Ser 
            20                  25                  30          
His His Leu Ser Ser Thr Asp Phe Pro Glu Leu Gly Gly Gly His Ala 
        35                  40                  45              
Tyr Cys Arg Asn Pro Gly Gly Gln Met Glu Gly Pro Trp Cys Phe Thr 
    50                  55                  60                  
Gln Asn Lys Asn Val Arg Met Glu Leu Cys Asp Val Pro Ser Cys 
65                  70                  75                  

<210> 23
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 9

<220> 
<221> VARIANT
<222> 2..3
<223> X is an amino acid which can be selected from any naturally
      occurring amino acid

<400> 23
Asp Xaa Xaa Ser Leu Asn Ile 
1               5           

<210> 24
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 9

<220> 
<221> VARIANT
<222> 2..4
<223> X is an amino acid which can be selected from any naturally
      occurring amino acid

<400> 24
Asp Xaa Xaa Xaa Ser Leu Asn Ile 
1               5               

<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 9

<220> 
<221> VARIANT
<222> 2..5
<223> X is an amino acid which can be selected from any naturally
      occurring amino acid

<400> 25
Asp Xaa Xaa Xaa Xaa Ser Leu Asn Ile 
1               5                   

<210> 26
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 26
Asp Asp Arg Trp Ser Leu Asn Ile 
1               5               

<210> 27
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 27
Asp Lys Gly Trp Ser Leu Asn Ile 
1               5               

<210> 28
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 28
Asp Thr Met Ser Leu Asn Ile 
1               5           

<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 29
Asp Trp Gly Asn Trp Ser Leu Asn Ile 
1               5                   

<210> 30
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 30
Asp Tyr Thr Ser Leu Asn Ile 
1               5           

<210> 31
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 31
Asp Ser Met Ser Leu Asn Ile 
1               5           

<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 32
Asp Gly Leu Thr Ser Leu Asn Ile 
1               5               

<210> 33
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 33
Asp Tyr Met Met Asn Ser Leu Asn Ile 
1               5                   

<210> 34
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 34
Asp Ser Arg Asn Ser Leu Asn Ile 
1               5               

<210> 35
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 35
Asp Ser Gly Val Val Ser Leu Asn Ile 
1               5                   

<210> 36
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 36
Asp Trp Thr Ser Leu Asn Ile 
1               5           

<210> 37
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 37
Asp Asn Gly Ser Thr Ser Leu Asn Ile 
1               5                   

<210> 38
<211> 9
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 10

<400> 38
Asp Ser Arg Arg Lys Ser Leu Asn Ile 
1               5                   

<210> 39
<211> 110
<212> PRT
<213> Artificial Sequence


<220> 
<223> VL1 sequence from Figure 11

<400> 39
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      
Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Asp 
            20                  25                  30          
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu 
        35                  40                  45              
Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gly Gly Tyr Ala Asp Ala Ser 
                85                  90                  95      
Tyr Arg Thr Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105                 110 

<210> 40
<211> 116
<212> PRT
<213> Artificial Sequence


<220> 
<223> VH1 sequence from Figure 11

<400> 40
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly 
1               5                   10                  15      
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Tyr 
            20                  25                  30          
Gly Val Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              
Ser Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys 
    50                  55                  60                  
Ser Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 
65                  70                  75                  80  
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      
Arg Asp Asp Arg Trp Ser Leu Asn Ile Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         
Thr Val Ser Ser 
        115     

<210> 41
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> LCDR1 sequence from Figure 11

<400> 41
Gln Ala Ser Gln Ser Ile Ser Ser Asp Leu Ser 
1               5                   10      

<210> 42
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> LCDR2 sequence from Figure 11

<400> 42
Gln Ala Ser Thr Leu Ala Ser 
1               5           

<210> 43
<211> 12
<212> PRT
<213> Artificial Sequence


<220> 
<223> LCDR3 sequence from Figure 11

<400> 43
Leu Gly Gly Tyr Ala Asp Ala Ser Tyr Arg Thr Ala 
1               5                   10          

<210> 44
<211> 5
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR1 sequence from Figure 11

<400> 44
Ser Tyr Gly Val Thr 
1               5   

<210> 45
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR2 sequence from Figure 11

<400> 45
Tyr Ile Asn Thr Ala Gly Asn Thr Tyr Tyr Ala Ser Trp Ala Lys Ser 
1               5                   10                  15      



<210> 46
<211> 46
<212> DNA
<213> Artificial Sequence


<220> 
<223> STOP primer

<400> 46
acctatttct gtgcgaggat tgtaatccct taacatctgg ggacca                    46


<210> 47
<211> 21
<212> DNA
<213> Artificial Sequence


<220> 
<223> Unirev primer

<400> 47
atctctcgca cagaaatagg t                                              21


<210> 48
<211> 48
<212> DNA
<213> Artificial Sequence


<220> 
<223> X2 primer

<220> 
<221> misc_difference
<222> 22,23,25,26
<223> /replace="wherein n is a or g or c or t"

<400> 48
acctatttct gtgcgagaga tnnknnktcc cttaacatct ggggacca                  48


<210> 49
<211> 51
<212> DNA
<213> Artificial Sequence


<220> 
<223> X3 primer

<220> 
<221> misc_difference
<222> 22,23,25,26,28,29
<223> /replace="wherein n is a or g or c or t"

<400> 49
acctatttct gtgcgagaga tnnknnknnk tcccttaaca tctggggacc a              51


<210> 50
<211> 54
<212> DNA
<213> Artificial Sequence


<220> 
<223> X4 primer

<220> 
<221> misc_difference
<222> 22,23,25,26,28,29,31,32
<223> /replace="wherein n is a or g or c or t"

<400> 50
acctatttct gtgcgagaga tnnknnknnk nnktccctta acatctgggg acca           54


<210> 51
<211> 6
<212> PRT
<213> Artificial Sequence


<220> 
<223> Further partial amino acid sequence of human ROR1 from Figure 8

<400> 51
Thr Phe Thr Ala Leu Arg 
1               5       

<210> 52
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> HCDR3 sequence from Figure 11

<400> 52
Asp Asp Arg Trp Ser Leu Asn Ile 
1               5               

<210> 53
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> Partial amino acid sequence of VhX3.12 and Vh401 from Figure 11

<400> 53
Gln Ser Val Lys 
1               

<210> 54
<211> 4
<212> PRT
<213> Artificial Sequence


<220> 
<223> Partial amino acid sequence of Vh3, VhX3.12 and Vh401 from Figure
      11

<400> 54
Asn Thr Asn Glu 
1               

